3 Sources
[1]
AI helps to detect antibiotic resistance
Researchers at the University of Zurich (UZH) have used artificial intelligence (AI) to help identify antibiotic-resistant bacteria. The team led by Adrian Egli, UZH professor at the Institute of Medical Microbiology, is the first to investigate how GPT-4, a powerful AI model developed by OpenAI, can be used to analyze antibiotic resistance. The researchers used AI to interpret a common laboratory test known as the Kirby-Bauer disk diffusion test, which helps doctors to determine which antibiotics can or can't fight a particular bacterial infection. Based on GPT-4, the scientists created the "EUCAST-GPT-expert," which follows strict EUCAST (European Committee on Antimicrobial Susceptibility Testing) guidelines for interpreting antimicrobial resistance mechanisms. By incorporating the latest data and expert rules, the system was tested on hundreds of bacterial isolates, helping to identify resistance to life-saving antibiotics. Human experts are more accurate -- but AI is faster "Antibiotic resistance is a growing threat worldwide, and we urgently need faster, more reliable tools to detect it," says Adrian Egli, who led the study. "Our research is the first step toward using AI in routine diagnostics to help doctors identify resistant bacteria more quickly." The AI system performed well in detecting certain types of resistance, but it wasn't perfect. While it was good at spotting bacteria resistant to certain antibiotics, it sometimes flagged bacteria as resistant when they were not, leading to possible delays in treatment. In comparison, human experts were more accurate in determining resistance, but the AI system could still help standardize and speed up the diagnostic process. Useful tool to support medical staff Despite the limitations, the study highlights the transformative potential of AI in healthcare. By offering a standardized approach to the interpretation of complex diagnostic tests, AI could eventually help reduce the variability and subjectivity that exists in manual readings, improving patient outcomes. Adrian Egli emphasizes that more testing and improvements are needed before this AI tool can be used in hospitals. "Our study is an important first step, but we are far from replacing human expertise. Instead, we see AI as a complementary tool that can support microbiologists in their work," he says. Curbing the global development of antibiotic resistance According to the study, AI has the potential to support the global response to antibiotic resistance development. With further development, AI-based diagnostics could help laboratories worldwide improve the speed and accuracy of detecting drug-resistant infections, helping to preserve the effectiveness of existing antibiotics.
[2]
UZH researchers harness AI to detect antibiotic resistance
University of Zurich (UZH)Oct 17 2024 Researchers at the University of Zurich (UZH) have used artificial intelligence (AI) to help identify antibiotic-resistant bacteria. The team led by Adrian Egli, UZH professor at the Institute of Medical Microbiology, is the first to investigate how GPT-4, a powerful AI model developed by OpenAI, can be used to analyze antibiotic resistance. The researchers used AI to interpret a common laboratory test known as the Kirby-Bauer disk diffusion test, which helps doctors to determine which antibiotics can or can't fight a particular bacterial infection. Based on GPT-4, the scientists created the "EUCAST-GPT-expert", which follows strict EUCAST (European Committee on Antimicrobial Susceptibility Testing) guidelines for interpreting antimicrobial resistance mechanisms. By incorporating the latest data and expert rules, the system was tested on hundreds of bacterial isolates, helping to identify resistance to life-saving antibiotics. Human experts are more accurate - but AI is faster "Antibiotic resistance is a growing threat worldwide, and we urgently need faster, more reliable tools to detect it," says Adrian Egli, who led the study. "Our research is the first step toward using AI in routine diagnostics to help doctors identify resistant bacteria more quickly." The AI system performed well in detecting certain types of resistance, but it wasn't perfect. While it was good at spotting bacteria resistant to certain antibiotics, it sometimes flagged bacteria as resistant when they were not, leading to possible delays in treatment. In comparison, human experts were more accurate in determining resistance, but the AI system could still help standardize and speed up the diagnostic process. Useful tool to support medical staff Despite the limitations, the study highlights the transformative potential of AI in healthcare. By offering a standardized approach to the interpretation of complex diagnostic tests, AI could eventually help reduce the variability and subjectivity that exists in manual readings, improving patient outcomes. Adrian Egli emphasizes that more testing and improvements are needed before this AI tool can be used in hospitals. Our study is an important first step, but we are far from replacing human expertise. Instead, we see AI as a complementary tool that can support microbiologists in their work." Adrian Egli, UZH professor at the Institute of Medical Microbiology Curbing the global development of antibiotic resistance According to the study, AI has the potential to support the global response to antibiotic resistance development. With further development, AI-based diagnostics could help laboratories worldwide improve the speed and accuracy of detecting drug-resistant infections, helping to preserve the effectiveness of existing antibiotics. University of Zurich (UZH) Journal reference: Giske, C. G., et al. (2024) GPT-4-based AI agents -- the new expert system for detection of antimicrobial resistance mechanisms?. Journal of Clinical Microbiology. doi.org/10.1128/jcm.00689-24.
[3]
GPT-4-based AI agents show promise for detecting antimicrobial resistance
Researchers at the University of Zurich (UZH) have used artificial intelligence (AI) to help identify antibiotic-resistant bacteria. The team led by Adrian Egli, UZH professor at the Institute of Medical Microbiology, is the first to investigate how GPT-4, a powerful AI model developed by OpenAI, can be used to analyze antibiotic resistance. The researchers used AI to interpret a common laboratory test known as the Kirby-Bauer disk diffusion test, which helps doctors to determine which antibiotics can or can't fight a particular bacterial infection. Based on GPT-4, the scientists created the "EUCAST-GPT-expert," which follows strict EUCAST (European Committee on Antimicrobial Susceptibility Testing) guidelines for interpreting antimicrobial resistance mechanisms. By incorporating the latest data and expert rules, the system was tested on hundreds of bacterial isolates, helping to identify resistance to life-saving antibiotics. The work was published in the Journal of Clinical Microbiology. "Antibiotic resistance is a growing threat worldwide, and we urgently need faster, more reliable tools to detect it," says Egli, who led the study. "Our research is the first step toward using AI in routine diagnostics to help doctors identify resistant bacteria more quickly." The AI system performed well in detecting certain types of resistance, but it wasn't perfect. While it was good at spotting bacteria resistant to certain antibiotics, it sometimes flagged bacteria as resistant when they were not, leading to possible delays in treatment. In comparison, human experts were more accurate in determining resistance, but the AI system could still help standardize and speed up the diagnostic process. Despite the limitations, the study highlights the transformative potential of AI in health care. By offering a standardized approach to the interpretation of complex diagnostic tests, AI could eventually help reduce the variability and subjectivity that exists in manual readings, improving patient outcomes. Egli emphasizes that more testing and improvements are needed before this AI tool can be used in hospitals. "Our study is an important first step, but we are far from replacing human expertise. Instead, we see AI as a complementary tool that can support microbiologists in their work," he says. According to the study, AI has the potential to support the global response to antibiotic resistance development. With further development, AI-based diagnostics could help laboratories worldwide improve the speed and accuracy of detecting drug-resistant infections, helping to preserve the effectiveness of existing antibiotics.
Share
Copy Link
Researchers at the University of Zurich have developed an AI system based on GPT-4 to interpret antibiotic resistance tests, potentially speeding up diagnostics but not yet matching human accuracy.
Researchers at the University of Zurich (UZH) have made a significant breakthrough in the fight against antibiotic resistance by harnessing the power of artificial intelligence. Led by Professor Adrian Egli from the Institute of Medical Microbiology, the team has pioneered the use of GPT-4, a sophisticated AI model developed by OpenAI, to analyze antibiotic resistance in bacteria 123.
The researchers developed an AI system called "EUCAST-GPT-expert" based on GPT-4. This system is designed to interpret the Kirby-Bauer disk diffusion test, a common laboratory procedure used to determine bacterial susceptibility to antibiotics. The AI follows strict guidelines set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for interpreting resistance mechanisms 12.
In trials involving hundreds of bacterial isolates, the AI system demonstrated promising results in detecting certain types of antibiotic resistance. However, it's not without limitations:
Accuracy: While effective at identifying resistant bacteria, the AI sometimes incorrectly flagged susceptible bacteria as resistant, potentially leading to treatment delays 123.
Comparison with Human Experts: Human experts still outperform the AI in terms of accuracy. Nevertheless, the AI system offers advantages in standardization and speed of the diagnostic process 123.
Despite its current limitations, the study highlights the transformative potential of AI in healthcare:
Standardization: AI could help reduce variability and subjectivity in manual readings of complex diagnostic tests 123.
Global Response: With further development, AI-based diagnostics could support the global fight against antibiotic resistance by improving the speed and accuracy of detecting drug-resistant infections worldwide 123.
Professor Egli emphasizes that while this research is a crucial first step, more testing and improvements are necessary before the AI tool can be implemented in hospitals. He views AI as a complementary tool to support microbiologists rather than a replacement for human expertise 123.
The study, published in the Journal of Clinical Microbiology, marks an important milestone in the application of AI to antibiotic resistance detection. As antibiotic resistance continues to pose a growing threat globally, this research opens up new possibilities for faster and more reliable diagnostic tools in the field of microbiology 3.
NVIDIA announces significant upgrades to its GeForce NOW cloud gaming service, including RTX 5080-class performance, improved streaming quality, and an expanded game library, set to launch in September 2025.
10 Sources
Technology
18 hrs ago
10 Sources
Technology
18 hrs ago
Nvidia is reportedly developing a new AI chip, the B30A, based on its latest Blackwell architecture for the Chinese market. This chip is expected to outperform the currently allowed H20 model, raising questions about U.S. regulatory approval and the ongoing tech trade tensions between the U.S. and China.
11 Sources
Technology
18 hrs ago
11 Sources
Technology
18 hrs ago
SoftBank Group has agreed to invest $2 billion in Intel, buying common stock at $23 per share. This strategic investment comes as Intel undergoes a major restructuring under new CEO Lip-Bu Tan, aiming to regain its competitive edge in the semiconductor industry, particularly in AI chips.
18 Sources
Business
10 hrs ago
18 Sources
Business
10 hrs ago
Databricks, a data analytics firm, is set to raise its valuation to over $100 billion in a new funding round, showcasing the strong investor interest in AI startups. The company plans to use the funds for AI acquisitions and product development.
7 Sources
Business
2 hrs ago
7 Sources
Business
2 hrs ago
OpenAI introduces ChatGPT Go, a new subscription plan priced at ₹399 ($4.60) per month exclusively for Indian users, offering enhanced features and affordability to capture a larger market share.
15 Sources
Technology
10 hrs ago
15 Sources
Technology
10 hrs ago